Business Wire

Parallel Bio Secures $21 Million in Series A to Advance Human-First Drug Discovery

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Parallel Bio, a biotech company pioneering human-first drug discovery, today announced it has raised $21 million Series A funding, led by AIX Ventures. The round ...

For some terminally ill patients, participating in drug testing is a way to give back

The efforts make drug testing more human-relevant while also reducing the suffering currently inflicted on laboratory animals ...

Combining talent and research: How S’pore lab advances discovery and approval of rare blood disorder therapy

With support from EDB and A*Star, Japanese biopharma leader Chugai is using its research base in Singapore to create new ...
Morningstar

Javelin Biotech Strengthens Board with Robin Robinson as Drug Discovery Shifts Towards Human-Based Models

Javelin, a pioneer in human-centric preclinical drug discovery, today announced the appointment of Robin Robinson, PhD to its Board of Directors, effective February 2025. This strategic addition comes ...